$PLTR

Walmart downgraded, Palantir upgraded: Wall Street's top analyst calls

Deutsche Bank upgraded Palantir (PLTR) to Buy, keeping a $200 target, citing an “exceptional” Q2. Oppenheimer upgraded Inspire Medical (INSP) to Outperform with an $85 target. UBS upgraded BBB Foods (TBBB) to Buy, $51 target. Several others were upgraded or downgraded ahead of earnings or on guidance, including Walmart (WMT) to Perform and Apple (AAPL) to Hold.

Original reporting
Published Aug 6, 2026, 1:30 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 6, 2026, 1:57 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Walmart downgraded, Palantir upgraded: Wall Street's top analyst calls — source image
Decision brief

The 30-second read

$PLTRBullishMed
01

Why it matters

Net effect is a sentiment reshuffle rather than a single fundamental shock. The most time-sensitive trading angle is Walmart’s downgrade ahead of its Aug. 20 earnings report; Apple’s downgrade is tied to guidance missing expectations; the rest are upgrades/initiations that can move short-term positioning but lack incremental disclosures in the text.

02

Market read

Traders can use the rating changes to adjust near-term positioning, but the article’s incremental information is limited because it mostly reports analyst opinions rather than new filings, trial readouts, or contract awards.

03

What to watch

For pre-earnings downgrades (Walmart) and guidance-miss framing (Apple), traders should watch for whether upcoming earnings confirm or contradict the analyst narrative, since the article provides no new guidance numbers.

Relevance 5/10Novelty 4/10Timing: pre-earnings positioning for Walmart ahead of Aug. 20; otherwise same-day analyst rating changes

Background

The piece is a multi-stock roundup of analyst rating changes and initiation notes, with a few items explicitly tied to recent earnings/guidance and one pre-earnings window (Walmart).

Company-level read

Ticker impact

$PLTRBullishMedium confidence
Context

Deutsche Bank upgraded Palantir to Buy from Hold, calling its Q2 report “exceptional” and keeping a $200 target.

Expected impact

Mildly positive bias for the next session(s) as traders price the upgrade; follow-through depends on broader tape.

Evidence & confidence

This is a fresh rating change with an unchanged target, which typically moves sentiment, but the article provides no incremental Palantir operational or financial figures.

$INSPBullishMedium confidence
Context

Oppenheimer upgraded Inspire Medical to Outperform, citing Q2 revenues of $201M slightly above estimates.

Expected impact

Moderately positive near-term drift, especially if the market had underweighted the Q2 beat.

Evidence & confidence

The article includes a concrete Q2 revenue figure and a rating change, but lacks guidance details or new trial/regulatory events.

$TBBBBullishLow confidence
Context

UBS upgraded BBB Foods to Buy from Neutral, highlighting same-store-sales ahead of inflation and value-seeking demand.

Expected impact

Slightly positive bias as the market re-rates the business quality narrative.

Evidence & confidence

The thesis is qualitative in the article and does not add new company disclosures beyond the analyst’s interpretation.

$REPLBullishLow confidence
Context

Leerink upgraded Replimune to Outperform, stating high conviction the FDA will grant RP-1 plus nivolumab accelerated approval.

Expected impact

Potentially strong positive reaction if traders treat it as a signal on FDA timing.

Evidence & confidence

The article provides no new clinical or regulatory filing details, only an analyst’s conviction statement.

$MDGLBullishLow confidence
Context

Wolfe Research upgraded Madrigal Pharmaceuticals to Outperform, arguing shares overcorrected on stage 4 liver fibrosis timing concerns.

Expected impact

Mild-to-moderate positive near-term, contingent on how the market interprets the “overcorrected” claim.

Evidence & confidence

No new trial results or regulatory updates are disclosed, so the catalyst is primarily sentiment and positioning.

$WMTBearishMedium confidence
Context

Oppenheimer downgraded Walmart to Perform from Outperform ahead of its Aug. 20 earnings report, citing a less compelling near-term outperformance case.

Expected impact

Negative bias into the earnings date, with volatility risk around the Aug. 20 report.

Evidence & confidence

The downgrade is time-relevant and explicitly tied to the pre-earnings window, but the article does not include new Walmart fundamentals.

$AAPLBearishMedium confidence
Context

China Renaissance downgraded Apple to Hold after in-line Q3 results and Q4 guidance that missed expectations.

Expected impact

Slightly negative near-term bias, especially if traders focus on guidance quality rather than results.

Evidence & confidence

The article cites both the in-line results and the guidance miss, which are concrete drivers, though no new guidance numbers are provided.

$EBAYBearishLow confidence
Context

Citizens downgraded eBay to Market Perform, arguing consensus estimates are too high.

Expected impact

Mild negative drift as the market reassesses expectations.

Evidence & confidence

The article provides no specific revised estimates or new operational disclosures.

Market effects

Broad set of analyst rating actions across software, semis, and healthcare; can shift relative performance within AI infrastructure, cyber, and managed care baskets.

Limited. Most actions are US-listed names; SK Hynix coverage is a global memory-cycle signal.

Memory-cycle optimism (SK Hynix) and AI infrastructure sentiment (CoreWeave) can marginally influence broader AI and semiconductor risk appetite.

Counterpoint

Because this is largely analyst rating/coverage activity, the market may already price the consensus view; without new company disclosures, follow-through can fade quickly.

Key entities

  • Walmart

    Oppenheimer downgraded to Perform ahead of Aug. 20 earnings.

  • Palantir

    Deutsche Bank upgraded to Buy, citing exceptional Q2.

  • Apple

    China Renaissance downgraded to Hold after in-line Q3 and Q4 guidance miss.

  • CoreWeave

    Piper Sandler initiated Overweight with a $151 target.

Related articles

$SKHYMed

SKHY Stock Slips Premarket After Korean Memory Giant Reveals $38B Expansion Plan Amid AI Hyperscaler Capex Frenzy

SK Hynix said it plans to invest 54 trillion won ($38B) to expand chipmaking in South Korea, including a new DRAM fab in Yongin and a NAND plant in Cheongju, with about two-thirds for DRAM, according to Bloomberg. Shares fell in premarket and Seoul. Results showed Q2 revenue up 257% YoY to 79.32T won and operating profit up 557% to 60.54T won.

$AAPLHighAI 9/10

Apple (AAPL) Q3 2026 Earnings Call Transcript

Apple’s Q3 FY2026 earnings call reported revenue of $109.4B (+16%) and diluted EPS of $2.02 (+29%), with tariff refunds contributing $0.11 to EPS and margin benefits. iPhone revenue rose to $54.3B, Services to $30.7B. Gross margin was 50.1%. September quarter guidance: revenue +9% to +11% and gross margin 47% to 48%.

$REPLMed

This Week at FDA: Inspection reorg, acting CBER chief eyes IND reforms, and more

FDA updates cover inspection reorganization plans, proposed IND reforms for early-stage biologics research, and accelerated approval of Replimune’s Tudriqev (vusolimogene oderparepvec-wtpg) with Bristol Myers Squibb’s Opdivo for melanoma after PD-1 regimens. Other items include FDA workshops, Seegene EUA for an assay, and multiple drug/device recalls.

$AMZNMedAI 8/10

Starlink’s average revenue per customer fell from $99 to $66 in three years, and the $11.57 billion satellite deal that just handed its only real rival a shortcut nobody in the industry saw coming

Starlink reported 10.3 million subscribers at end of Q1 2026, up 105% year over year, but average revenue per user fell to $66 per month from $86 a year earlier and $99 in 2023, citing international expansion and lower-priced plans. Amazon agreed to buy Globalstar for about $11.57B, offering $90/share, to gain spectrum and enable direct-to-device services and Apple iPhone and Apple Watch connectivity.

$NKEMed

Trump’s Invalidated Tariffs Trigger $100 Billion in Corporate Refunds

The U.S. Supreme Court invalidated President Trump’s “Liberation Day” tariffs under the IEEPA. According to U.S. Customs and Border Protection, about $100 billion in tariff refunds, including interest, has been certified and sent to Treasury for disbursement. CBP collected about $166 billion, and refunds are flowing to importers such as Nike, Walmart, Apple, Ford, Nintendo, and Amazon.

$NBISMed

NBIS, CSCO, SLS Stocks Hit 52-Week Highs Today: What's Behind The Surge?

Nebius Group (NBIS), Cisco Systems (CSCO), and Sellas Life Sciences Group (SLS) hit 52-week highs. Nebius reported Q1 revenue of $399M, up 684% YoY, and raised 2026 ARR guidance to $7B-$9B, plus access to up to 1.2 GW power for an AI facility. Cisco raised AI infrastructure order forecast to about $9B and reported Q3 revenue of $15.8B. SLS said its Phase 3 REGAL AML study is nearing a final event threshold and reported $107M+ cash.